Review Article: Sexuality and Risk-Reducing Salpingo-oophorectomy

2017 ◽  
Vol 27 (4) ◽  
pp. 847-852 ◽  
Author(s):  
Paige E. Tucker ◽  
Paul A. Cohen

IntroductionWomen with familial cancer syndromes such as hereditary breast and ovarian cancer syndrome (BRCA1 and BRCA2) and Lynch syndrome are at a significantly increased risk of developing ovarian cancer and are advised to undergo prophylactic removal of their ovaries and fallopian tubes at age 35 to 40 years, after childbearing is complete.MethodsA comprehensive literature search of studies on risk-reducing salpingo-oophorectomy (RRSO), sexuality, and associated issues was conducted in MEDLINE databases.ResultsRisk-reducing salpingo-oophorectomy can significantly impact on a woman’s psychological and sexual well-being, with women wishing they had received more information about this prior to undergoing surgery. The most commonly reported sexual symptoms experienced are vaginal dryness and reduced libido. Women who are premenopausal at the time of surgery may experience a greater decline in sexual function, with menopausal hormone therapy improving but not alleviating sexual symptoms. Pharmacological treatments including testosterone patches and flibanserin are available but have limited safety data in this group.ConclusionsDespite the high rates of sexual difficulties after RRSO, patient satisfaction with the decision to undergo surgery remains high. Preoperative counseling with women who are considering RRSO should include discussion of its potential sexual effects and the limitations of menopausal hormone therapy in managing symptoms of surgical menopause.

Menopause ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Mark van Barele ◽  
Chistien C.M. Buis ◽  
Monique M.A. Brood-van Zanten ◽  
H. (Lena) C. van Doorn ◽  
Katja N. Gaarenstroom ◽  
...  

PLoS ONE ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. e0169673 ◽  
Author(s):  
Ingrid E. Fakkert ◽  
Eveline van der Veer ◽  
Elske Marije Abma ◽  
Joop D. Lefrandt ◽  
Bruce H. R. Wolffenbuttel ◽  
...  

2015 ◽  
Vol 13 ◽  
pp. 13-17 ◽  
Author(s):  
Ashley S. Felix ◽  
Kristen Bunch ◽  
Hannah P. Yang ◽  
Hannah Arem ◽  
Britton Trabert ◽  
...  

2009 ◽  
Vol 5 (5) ◽  
pp. 463-465

Researchers suggest that the risk of ovarian cancer should be taken into account by women considering the use of hormone therapy.


2015 ◽  
Vol 51 (3) ◽  
pp. 400-408 ◽  
Author(s):  
Ingrid E. Fakkert ◽  
Elske Marije Abma ◽  
Iris G. Westrik ◽  
Joop D. Lefrandt ◽  
Bruce H.R. Wolffenbuttel ◽  
...  

2002 ◽  
Vol 9 (6) ◽  
pp. 457-465 ◽  
Author(s):  
Mark E. Robson

Background Hereditary predisposition to breast and ovarian cancer, most commonly due to germline mutations in BRCA1 and BRCA2, has been recognized for many years. The optimal clinical management of individuals with such a predisposition is not yet completely defined. Methods The current literature regarding the clinical management of individuals at risk for hereditary breast and ovarian cancer was reviewed. Results Women with germline BRCA1 or BRCA2 mutations are at substantially increased risk for breast and ovarian cancer, although the risks may not be as high as originally reported. Current surveillance options are restricted in their effectiveness by both host and tumor factors as well as limitations of the techniques. Surgical prevention options, while effective, may be complicated by physical or psychological morbidity. Nonsurgical prevention options are under development. Conclusions The ability to define women as being at hereditary risk for breast and ovarian cancer facilitates the use of specialized surveillance and prevention strategies. Genetic testing, which plays a role in defining risk, requires careful pre- and post-test counseling to discuss the limitations of testing itself and available management strategies.


Maturitas ◽  
2015 ◽  
Vol 81 (1) ◽  
pp. 3-4 ◽  
Author(s):  
Faustino R. Pérez-López ◽  
Margaret Rees

Sign in / Sign up

Export Citation Format

Share Document